New Advances in the Development of New Drugs and Treatment Targets for Brain Cancers (2nd Edition)

Dear Colleagues,

Brain malignancies pose a substantial obstacle for the field of oncology and the advancement of pharmaceuticals. Historically, the treatment of brain tumors has been challenging due to their physical and molecular characteristics. The tumor's exposure to systemic therapy may be diminished by the blood–tumor barrier (BTB), which may differ from the normal blood–brain barrier (BBB) and frequently complicate complete surgery. Moreover, brain tumors possess microenvironmental characteristics that are remarkably distinct and intricately associated with developmental factors. The tumor microenvironment (TME) is composed primarily of specialized cells such as brain endothelial cells, astrocytes, neurons and microglia, which are concentrated in the brain. In addition, it has been shown that unique subpopulations of cells derived from the bone marrow infiltrate both primary and metastatic brain malignancies. The potential of the TME as both a diagnostic marker and a therapeutic target for brain malignancies has been established.

We declare a call for papers for the second series of our Special Issue "New Advances in the Development of New Drugs and Treatment Targets for Brain Cancers (2nd Edition)" with great enthusiasm. This series demonstrates our dedication to collecting and presenting the most recent research, advancements and difficulties in the field of brain tumors. This resource enhances the comprehension of various primary brain cancers by examining novel therapy approaches and targeted medications, while delving into the significance of brain tumors at the cellular and molecular levels. For this second series, we are specifically seeking papers that expand upon the research offered in the first series. We are looking for fresh viewpoints, approaches to unresolved issues and creative solutions.

Dr. Luis Exequiel Ibarra
Dr. Laura Natalia Milla Sanabria
Dr. Nuria Arias-Ramos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• gliomas
• targeted therapy
• blood–brain barrier
• tumor microenvironment
• molecular and cellular biology